# A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer

> **NCT00553813** · PHASE2 · TERMINATED · sponsor: **Cortice Biosciences, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** TPI 287

## Key facts

- **NCT ID:** NCT00553813
- **Lead sponsor:** Cortice Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-09
- **Final completion:** 2010-04
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Insufficient funding
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00553813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00553813, "A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00553813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*